Programmes
Overview
We are developing a portfolio of proprietary and partnered programmes in fibrosis and solid tumours using our pioneering human extracellular matrix platform, initially focused on the liver, intestine and pancreas.
Our pipeline
Our human extracellular matrix (ECM)-based discovery platform is applicable to multiple organs, indications and fields.
By recognising the impact of the natural cell microenvironment in our in vitro models, we are better able to identify and validate relevant drug targets, determine mechanisms of action, and more accurately predict the efficacy of candidate therapeutics, thereby accelerating drug discovery.
Scroll left to right to view full pipeline
| Indication | ECM and Target ID | Target Validation | Drug Discovery | IND Enabling | Partners |
|---|---|---|---|---|---|
| Primary sclerosing cholangitis (PSC) | 100 | 100 | 10 | ||
| Nonalcoholic steatohepatitis (NASH) | 100 | 50 | https://engitix.com/wp-content/uploads/2021/06/Logo_Takeda_350.png | ||
| Intestinal fibrostenosis in inflammatory bowel disease (IBD) | 80 | https://engitix.com/wp-content/uploads/2021/06/Logo_Takeda_350.png | |||
| Pancreatic adenocarcinoma (PDAC) and liver metastasis | 100 | 75 | |||
| Hepatocellular carcinoma (HCC) | 100 | 40 |
